Cargando…
Myocardial Hypertrophic Preconditioning Attenuates Cardiomyocyte Hypertrophy and Slows Progression to Heart Failure Through Upregulation of S100A8/A9
BACKGROUND—: Transient preceding brief ischemia provides potent cardioprotection against subsequent long ischemia, termed ischemic preconditioning. Here, we hypothesized that transient short-term hypertrophic stimulation would induce the expression of hypertrophy regression genes and render the hear...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415966/ https://www.ncbi.nlm.nih.gov/pubmed/25820336 http://dx.doi.org/10.1161/CIRCULATIONAHA.114.013789 |
_version_ | 1782369161136046080 |
---|---|
author | Wei, Xuan Wu, Bing Zhao, Jing Zeng, Zhi Xuan, Wanling Cao, Shiping Huang, Xiaobo Asakura, Masanori Xu, Dingli Bin, Jianping Kitakaze, Masafumi Liao, Yulin |
author_facet | Wei, Xuan Wu, Bing Zhao, Jing Zeng, Zhi Xuan, Wanling Cao, Shiping Huang, Xiaobo Asakura, Masanori Xu, Dingli Bin, Jianping Kitakaze, Masafumi Liao, Yulin |
author_sort | Wei, Xuan |
collection | PubMed |
description | BACKGROUND—: Transient preceding brief ischemia provides potent cardioprotection against subsequent long ischemia, termed ischemic preconditioning. Here, we hypothesized that transient short-term hypertrophic stimulation would induce the expression of hypertrophy regression genes and render the heart resistant to subsequent hypertrophic stress, and slow the progression to heart failure, as well. METHODS AND RESULTS—: Cardiomyocyte hypertrophy was induced in mice by either transverse aortic constriction or an infusion of phenylephrine, and in neonatal rat ventricular cardiomyocytes by norepinephrine exposures. In the preconditioning groups, hypertrophic stimulation was provided for 1 to 7 days and then withdrawn for several days by either aortic debanding or discontinuing phenylephrine or norepinephrine treatment, followed by subsequent reexposure to the hypertrophic stimulus for the same period as in the control group. One or 6 weeks after transverse aortic constriction, the heart weight/body weight ratio was lower in the preconditioning group than in the control group, whereas the lung weight/body weight ratio was significantly decreased 6 weeks after transverse aortic constriction. Similar results were obtained in mice receiving phenylephrine infusion and neonatal rat ventricular cardiomyocytes stimulated with norepinephrine. Both mRNA and protein expression of S100A8 and S100A9 showed significant upregulation after the removal of hypertrophic stimulation and persisted for 6 weeks in response to reimposition of transverse aortic constriction. The treatment with recombinant S100A8/A9 inhibited norepinephrine-induced myocyte hypertrophy and reduced the expression of calcineurin and NFATc3, but the silencing of S100A8/A9 prevented such changes. CONCLUSIONS—: Preconditioning with prohypertrophic factors exerts an antihypertrophic effect and slows the progression of heart failure, indicating the existence of the phenomenon for hypertrophic preconditioning. |
format | Online Article Text |
id | pubmed-4415966 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-44159662015-05-11 Myocardial Hypertrophic Preconditioning Attenuates Cardiomyocyte Hypertrophy and Slows Progression to Heart Failure Through Upregulation of S100A8/A9 Wei, Xuan Wu, Bing Zhao, Jing Zeng, Zhi Xuan, Wanling Cao, Shiping Huang, Xiaobo Asakura, Masanori Xu, Dingli Bin, Jianping Kitakaze, Masafumi Liao, Yulin Circulation Original Articles BACKGROUND—: Transient preceding brief ischemia provides potent cardioprotection against subsequent long ischemia, termed ischemic preconditioning. Here, we hypothesized that transient short-term hypertrophic stimulation would induce the expression of hypertrophy regression genes and render the heart resistant to subsequent hypertrophic stress, and slow the progression to heart failure, as well. METHODS AND RESULTS—: Cardiomyocyte hypertrophy was induced in mice by either transverse aortic constriction or an infusion of phenylephrine, and in neonatal rat ventricular cardiomyocytes by norepinephrine exposures. In the preconditioning groups, hypertrophic stimulation was provided for 1 to 7 days and then withdrawn for several days by either aortic debanding or discontinuing phenylephrine or norepinephrine treatment, followed by subsequent reexposure to the hypertrophic stimulus for the same period as in the control group. One or 6 weeks after transverse aortic constriction, the heart weight/body weight ratio was lower in the preconditioning group than in the control group, whereas the lung weight/body weight ratio was significantly decreased 6 weeks after transverse aortic constriction. Similar results were obtained in mice receiving phenylephrine infusion and neonatal rat ventricular cardiomyocytes stimulated with norepinephrine. Both mRNA and protein expression of S100A8 and S100A9 showed significant upregulation after the removal of hypertrophic stimulation and persisted for 6 weeks in response to reimposition of transverse aortic constriction. The treatment with recombinant S100A8/A9 inhibited norepinephrine-induced myocyte hypertrophy and reduced the expression of calcineurin and NFATc3, but the silencing of S100A8/A9 prevented such changes. CONCLUSIONS—: Preconditioning with prohypertrophic factors exerts an antihypertrophic effect and slows the progression of heart failure, indicating the existence of the phenomenon for hypertrophic preconditioning. Lippincott Williams & Wilkins 2015-04-28 2015-04-28 /pmc/articles/PMC4415966/ /pubmed/25820336 http://dx.doi.org/10.1161/CIRCULATIONAHA.114.013789 Text en © 2015 The Authors. Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDervis (https://creativecommons.org/licenses/by-nc-nd/3.0/) License, which permits use, distribution, and reproduction in any medium, provided that the Contribution is properly cited, the use is non-commercial, and no modifications or adaptations are made. |
spellingShingle | Original Articles Wei, Xuan Wu, Bing Zhao, Jing Zeng, Zhi Xuan, Wanling Cao, Shiping Huang, Xiaobo Asakura, Masanori Xu, Dingli Bin, Jianping Kitakaze, Masafumi Liao, Yulin Myocardial Hypertrophic Preconditioning Attenuates Cardiomyocyte Hypertrophy and Slows Progression to Heart Failure Through Upregulation of S100A8/A9 |
title | Myocardial Hypertrophic Preconditioning Attenuates Cardiomyocyte Hypertrophy and Slows Progression to Heart Failure Through Upregulation of S100A8/A9 |
title_full | Myocardial Hypertrophic Preconditioning Attenuates Cardiomyocyte Hypertrophy and Slows Progression to Heart Failure Through Upregulation of S100A8/A9 |
title_fullStr | Myocardial Hypertrophic Preconditioning Attenuates Cardiomyocyte Hypertrophy and Slows Progression to Heart Failure Through Upregulation of S100A8/A9 |
title_full_unstemmed | Myocardial Hypertrophic Preconditioning Attenuates Cardiomyocyte Hypertrophy and Slows Progression to Heart Failure Through Upregulation of S100A8/A9 |
title_short | Myocardial Hypertrophic Preconditioning Attenuates Cardiomyocyte Hypertrophy and Slows Progression to Heart Failure Through Upregulation of S100A8/A9 |
title_sort | myocardial hypertrophic preconditioning attenuates cardiomyocyte hypertrophy and slows progression to heart failure through upregulation of s100a8/a9 |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415966/ https://www.ncbi.nlm.nih.gov/pubmed/25820336 http://dx.doi.org/10.1161/CIRCULATIONAHA.114.013789 |
work_keys_str_mv | AT weixuan myocardialhypertrophicpreconditioningattenuatescardiomyocytehypertrophyandslowsprogressiontoheartfailurethroughupregulationofs100a8a9 AT wubing myocardialhypertrophicpreconditioningattenuatescardiomyocytehypertrophyandslowsprogressiontoheartfailurethroughupregulationofs100a8a9 AT zhaojing myocardialhypertrophicpreconditioningattenuatescardiomyocytehypertrophyandslowsprogressiontoheartfailurethroughupregulationofs100a8a9 AT zengzhi myocardialhypertrophicpreconditioningattenuatescardiomyocytehypertrophyandslowsprogressiontoheartfailurethroughupregulationofs100a8a9 AT xuanwanling myocardialhypertrophicpreconditioningattenuatescardiomyocytehypertrophyandslowsprogressiontoheartfailurethroughupregulationofs100a8a9 AT caoshiping myocardialhypertrophicpreconditioningattenuatescardiomyocytehypertrophyandslowsprogressiontoheartfailurethroughupregulationofs100a8a9 AT huangxiaobo myocardialhypertrophicpreconditioningattenuatescardiomyocytehypertrophyandslowsprogressiontoheartfailurethroughupregulationofs100a8a9 AT asakuramasanori myocardialhypertrophicpreconditioningattenuatescardiomyocytehypertrophyandslowsprogressiontoheartfailurethroughupregulationofs100a8a9 AT xudingli myocardialhypertrophicpreconditioningattenuatescardiomyocytehypertrophyandslowsprogressiontoheartfailurethroughupregulationofs100a8a9 AT binjianping myocardialhypertrophicpreconditioningattenuatescardiomyocytehypertrophyandslowsprogressiontoheartfailurethroughupregulationofs100a8a9 AT kitakazemasafumi myocardialhypertrophicpreconditioningattenuatescardiomyocytehypertrophyandslowsprogressiontoheartfailurethroughupregulationofs100a8a9 AT liaoyulin myocardialhypertrophicpreconditioningattenuatescardiomyocytehypertrophyandslowsprogressiontoheartfailurethroughupregulationofs100a8a9 |